TCF7L2/TCF4 Rabbit Polyclonal Antibody (R1401-11)

UNIPROT #

Q9NQB0

PROTEIN NAME

TCF7L2/TCF4

SYNONYMS

bHLHb19 antibody;Class B basic helix-loop-helix protein 19 antibody;E2 2 antibody;FECD3 antibody;Immunoglobulin transcription factor 2 antibody;ITF 2 antibody;ITF-2 antibody;ITF2 antibody;ITF2_HUMAN antibody;MGC149723 antibody;MGC149724 antibody;PTHS antibody;SEF 2 antibody;SEF-2 antibody;SEF2 1 antibody;SEF2 1A antibody;SEF2 1B antibody;SEF2 1D antibody;SEF2 antibody;SL3 3 enhancer factor 2 antibody;SL3-3 enhancer factor 2 antibody;TCF 4 antibody;TCF-4 antibody;TCF4 antibody;Transcription factor 4 antibody;Transcription factor 4, isoform C antibody;Transcription factor 4, isoform D antibody;Transcription factor 4, isoform E antibody;Transcription factor 4, isoform L antibody;Transcription factor 4, isoform M antibody;Transcription factor 4, isoform R antibody

SEQUENCE SIMILARITIES

Belongs to the TCF/LEF family.

TISSUE SPECIFICITY

Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.

DEVELOPMENTAL STAGE

Highly expressed in crypt regions and barely detectable in villi in epithelium from fetal small intestine at week 16. At week 22 expression in villi had increased strongly.

POST-TRANSLATIONAL MODIFICATION

In vitro, phosphorylated by TNIK.; Phosphorylated at Thr-201 and/or Thr-212 by NLK. Phosphorylation by NLK at these sites inhibits DNA-binding by TCF7L2/TCF4, thereby preventing transcriptional activation of target genes of the canonical Wnt/beta-catenin signaling pathway.; Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylation is enhanced by SENP2. Sumoylation/desumoylation regulates TCF7L2/TCF4 transcription activity in the Wnt/beta-catenin signaling pathway without altering interaction with CTNNB1 nor binding to DNA.

SUBCELLULAR LOCATION

Nucleus

FUNCTION

TCF7L2 is a transcription factor influencing the transcription of several genes thereby exerting a large variety of functions within the cell. It is a member of the Wnt signaling pathway. Stimulation of the pathway leads to the association of β-catenin with BCL9, translocation to the nucleus, and association with TCF7L2, which in turn results in the activation of Wnt target genes, specifically repressing proglucagon synthesis in enteroendocrine cells. TCF7L2 is implicated in a large variety of diseases. Several single nucleotide polymorphisms are associated with type 2 diabetes. In European populations it was found to be a major determinant of type 2 risk. A frameshift mutation of TCF7L2 is implicated in colorectal cancer .Variants of the gene are most likely involved in many other cancer types